Does treatment with somatostatin analogs differ in the uptake of normal target organs and malignant lesions on 68Ga-DOTATATE PET/CT imaging?
Abstract Objective: Somatostatin analogs (SSA) are used in treating low-grade neuroendocrine tumors, mainly because of their antiproliferative effect. 68Ga tetraazacyclododecantetraacetic acid-DPhe1-Tyr3-octreotate (DOTATATE) PET/CT as somatostatin receptor imaging has been widely used in recent ye...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Selcuk University Press
2022-08-01
|
| Series: | Genel Tıp Dergisi |
| Subjects: | |
| Online Access: | https://dergipark.org.tr/tr/download/article-file/2581308 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841563616454639616 |
|---|---|
| author | Çağlagül Erol Ahmet Volkan Çelik Özlem Şahin Gonca Kara Gedik Hasan Önner Farise Yılmaz |
| author_facet | Çağlagül Erol Ahmet Volkan Çelik Özlem Şahin Gonca Kara Gedik Hasan Önner Farise Yılmaz |
| author_sort | Çağlagül Erol |
| collection | DOAJ |
| description | Abstract
Objective:
Somatostatin analogs (SSA) are used in treating low-grade neuroendocrine tumors, mainly because of their antiproliferative effect. 68Ga tetraazacyclododecantetraacetic acid-DPhe1-Tyr3-octreotate (DOTATATE) PET/CT as somatostatin receptor imaging has been widely used in recent years. However, there are conflicting publications in the literature, although there are guidelines for discontinuing the use of SSA before imaging. This study aims to investigate the effect of SSAs on Somatostatin receptor imaging.
Material and Method: We retrospectively analyzed 253 patients who underwent 68Ga-DOTATATE PET/CT imaging between 2018 and 2022. Among these patients, those with low grades (Grade 1 and Grade 2) using SSA were included in the study. SUVmax (maximum standard uptake volume) of normal target organs, primary tumors, and metastases with the highest SUVmax in each organ were compared before and after SSA treatment.
Results: 28 patients (16 females; 12 males, age [mean±SD], 54.82±14.27, range 18-78) with low-grade (Grade 1 and 2) NET and 68Ga-DOTATATE PET/CT imaging with SSA therapy were included in the study. Although SUVmax was decreased in the values measured after SSA application in the liver and spleen, it was not statistically significant (p>0.05). There was no significant difference between SUVmax values in primary tumors and metastatic lesions in the liver, bone, lung, or lymph nodes before and after SSA application (P> 0.05).
Conclusion: In conclusion, these drugs do not need to be discontinued before 68Ga-DOTATATE PET/CT imaging for treatment follow-up in neuroendocrine tumor patients using somatostatin analogs. In addition, these drugs may help report interpretation by increasing the intensity of metastatic lesions in the liver and spleen. |
| format | Article |
| id | doaj-art-6097d084e2e044abbb227e4f0f6df701 |
| institution | Kabale University |
| issn | 2602-3741 |
| language | English |
| publishDate | 2022-08-01 |
| publisher | Selcuk University Press |
| record_format | Article |
| series | Genel Tıp Dergisi |
| spelling | doaj-art-6097d084e2e044abbb227e4f0f6df7012025-01-02T23:43:05ZengSelcuk University PressGenel Tıp Dergisi2602-37412022-08-0132446446810.54005/geneltip.1157941154Does treatment with somatostatin analogs differ in the uptake of normal target organs and malignant lesions on 68Ga-DOTATATE PET/CT imaging?Çağlagül Erol0Ahmet Volkan Çelik1Özlem Şahin2Gonca Kara Gedik3Hasan Önner4Farise Yılmaz5NECMETTIN ERBAKAN UNIVERSITYSELCUK UNIVERSITYNECMETTIN ERBAKAN UNIVERSITYSELCUK UNIVERSITYSELCUK UNIVERSITYSELCUK UNIVERSITYAbstract Objective: Somatostatin analogs (SSA) are used in treating low-grade neuroendocrine tumors, mainly because of their antiproliferative effect. 68Ga tetraazacyclododecantetraacetic acid-DPhe1-Tyr3-octreotate (DOTATATE) PET/CT as somatostatin receptor imaging has been widely used in recent years. However, there are conflicting publications in the literature, although there are guidelines for discontinuing the use of SSA before imaging. This study aims to investigate the effect of SSAs on Somatostatin receptor imaging. Material and Method: We retrospectively analyzed 253 patients who underwent 68Ga-DOTATATE PET/CT imaging between 2018 and 2022. Among these patients, those with low grades (Grade 1 and Grade 2) using SSA were included in the study. SUVmax (maximum standard uptake volume) of normal target organs, primary tumors, and metastases with the highest SUVmax in each organ were compared before and after SSA treatment. Results: 28 patients (16 females; 12 males, age [mean±SD], 54.82±14.27, range 18-78) with low-grade (Grade 1 and 2) NET and 68Ga-DOTATATE PET/CT imaging with SSA therapy were included in the study. Although SUVmax was decreased in the values measured after SSA application in the liver and spleen, it was not statistically significant (p>0.05). There was no significant difference between SUVmax values in primary tumors and metastatic lesions in the liver, bone, lung, or lymph nodes before and after SSA application (P> 0.05). Conclusion: In conclusion, these drugs do not need to be discontinued before 68Ga-DOTATATE PET/CT imaging for treatment follow-up in neuroendocrine tumor patients using somatostatin analogs. In addition, these drugs may help report interpretation by increasing the intensity of metastatic lesions in the liver and spleen.https://dergipark.org.tr/tr/download/article-file/258130868ga-dotatate pet/ctsomatostatin analogsneuroendocrine tumors.nöroendokrin tümörler68ga-dotatate pet/btsomatostatin analogları |
| spellingShingle | Çağlagül Erol Ahmet Volkan Çelik Özlem Şahin Gonca Kara Gedik Hasan Önner Farise Yılmaz Does treatment with somatostatin analogs differ in the uptake of normal target organs and malignant lesions on 68Ga-DOTATATE PET/CT imaging? Genel Tıp Dergisi 68ga-dotatate pet/ct somatostatin analogs neuroendocrine tumors. nöroendokrin tümörler 68ga-dotatate pet/bt somatostatin analogları |
| title | Does treatment with somatostatin analogs differ in the uptake of normal target organs and malignant lesions on 68Ga-DOTATATE PET/CT imaging? |
| title_full | Does treatment with somatostatin analogs differ in the uptake of normal target organs and malignant lesions on 68Ga-DOTATATE PET/CT imaging? |
| title_fullStr | Does treatment with somatostatin analogs differ in the uptake of normal target organs and malignant lesions on 68Ga-DOTATATE PET/CT imaging? |
| title_full_unstemmed | Does treatment with somatostatin analogs differ in the uptake of normal target organs and malignant lesions on 68Ga-DOTATATE PET/CT imaging? |
| title_short | Does treatment with somatostatin analogs differ in the uptake of normal target organs and malignant lesions on 68Ga-DOTATATE PET/CT imaging? |
| title_sort | does treatment with somatostatin analogs differ in the uptake of normal target organs and malignant lesions on 68ga dotatate pet ct imaging |
| topic | 68ga-dotatate pet/ct somatostatin analogs neuroendocrine tumors. nöroendokrin tümörler 68ga-dotatate pet/bt somatostatin analogları |
| url | https://dergipark.org.tr/tr/download/article-file/2581308 |
| work_keys_str_mv | AT caglagulerol doestreatmentwithsomatostatinanalogsdifferintheuptakeofnormaltargetorgansandmalignantlesionson68gadotatatepetctimaging AT ahmetvolkancelik doestreatmentwithsomatostatinanalogsdifferintheuptakeofnormaltargetorgansandmalignantlesionson68gadotatatepetctimaging AT ozlemsahin doestreatmentwithsomatostatinanalogsdifferintheuptakeofnormaltargetorgansandmalignantlesionson68gadotatatepetctimaging AT goncakaragedik doestreatmentwithsomatostatinanalogsdifferintheuptakeofnormaltargetorgansandmalignantlesionson68gadotatatepetctimaging AT hasanonner doestreatmentwithsomatostatinanalogsdifferintheuptakeofnormaltargetorgansandmalignantlesionson68gadotatatepetctimaging AT fariseyılmaz doestreatmentwithsomatostatinanalogsdifferintheuptakeofnormaltargetorgansandmalignantlesionson68gadotatatepetctimaging |